Eye trouble uncovers stage 4 lung cancer; endurance athlete defies odds with new therapies
A former Ironman triathlete’s vision problems led doctors to diagnose stage 4 lung cancer, and after a sequence of targeted therapies—including afatinib, osimertinib, and the IV drug amivantamab (Rybrevant)—he has lived seven years beyond an initial 12–24 month prognosis and now raises awareness through advocacy and endurance events.